Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription Articles published in Bone Marrow Transplant Retrieve available abstracts of 216 articles: HTML format

Single Articles

April 2024
1. FILIOGLOU D, Truscott L, Reddivalla N, Katsanis E, et al
   Outcomes of haploidentical bone marrow transplantation in infant acute leukemia: a single center experience.
   Bone Marrow Transplant. 2024 Apr 9. doi: 10.1038/s41409-024-02281.
   PubMed    
   
   
   
2. BARANWAL A, Mangaonkar A, Shah MV, Al-Kali A, et al
   EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant.
   Bone Marrow Transplant. 2024;59:558-560.
   PubMed    
   
   
   March 2024
3. MAFFINI E, Labopin M, Kroger N, Finke J, et al
   Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
   Bone Marrow Transplant. 2024 Mar 30. doi: 10.1038/s41409-024-02275.
   PubMed     Abstract available
   
   
   
4. PARK S, Bang SY, Kwag D, Lee JH, et al
   Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
   Bone Marrow Transplant. 2024 Mar 4. doi: 10.1038/s41409-024-02255.
   PubMed     Abstract available
   
   
   February 2024
5. HIROSE A, Koh H, Nakamae M, Nakashima Y, et al
   A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
   Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231.
   PubMed    
   
   
   
6. YANADA M, Yano S, Kuwatsuka Y, Kawamura K, et al
   The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.
   Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02222.
   PubMed     Abstract available
   
   
   
7. SPYRIDONIDIS A, Labopin M, Gedde-Dahl T, Ganser A, et al
   Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation.
   Bone Marrow Transplant. 2024;59:217-223.
   PubMed     Abstract available
   
   
   January 2024
8. XIAO M, Zhou J, Zhu X, He Y, et al
   A prognostic score system in adult T-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation.
   Bone Marrow Transplant. 2024 Jan 24. doi: 10.1038/s41409-024-02211.
   PubMed     Abstract available
   
   
   
9. CHEN W, Shi J, Luo Y, Yu J, et al
   Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
   Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
   PubMed    
   
   
   
10. ALBINGER N, Muller S, Kostyra J, Kuska J, et al
    Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Jan 22. doi: 10.1038/s41409-023-02180.
    PubMed     Abstract available
    
    
    
11. SHARMA A, Galimard JE, Pryce A, Bhoopalan SV, et al
    Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.
    Bone Marrow Transplant. 2024 Jan 15. doi: 10.1038/s41409-024-02197.
    PubMed     Abstract available
    
    
    
12. VELARDI A, Mancusi A, Ruggeri L, Pierini A, et al
    How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia.
    Bone Marrow Transplant. 2024 Jan 11. doi: 10.1038/s41409-024-02199.
    PubMed     Abstract available
    
    
    
13. ARCURI LJ
    Re: Prophylactic versus preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Bone Marrow Transplant. 2024 Jan 10. doi: 10.1038/s41409-023-02186.
    PubMed    
    
    
    
14. SADOWSKA-KLASA A, Zaucha JM, Labopin M, Bourhis JH, et al
    Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02192.
    PubMed     Abstract available
    
    
    
15. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
    Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
    PubMed     Abstract available
    
    
    
16. RAVINDRA N, Dillon LW, Gui G, Smith M, et al
    Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.
    Bone Marrow Transplant. 2024 Jan 5. doi: 10.1038/s41409-023-02189.
    PubMed    
    
    
    December 2023
17. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    PubMed    
    
    
    
18. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
    Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
    Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
    PubMed     Abstract available
    
    
    
19. POIRE X, Labopin M, Polge E, Ganser A, et al
    Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype.
    Bone Marrow Transplant. 2023 Dec 13. doi: 10.1038/s41409-023-02167.
    PubMed     Abstract available
    
    
    
20. DUQUE-AFONSO J, Finke J, Ngoya M, Galimard JE, et al
    Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT
    Bone Marrow Transplant. 2023 Dec 2. doi: 10.1038/s41409-023-02150.
    PubMed     Abstract available
    
    
    November 2023
21. CAO LQ, Huo WX, Zhang XH, Xu LP, et al
    Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients.
    Bone Marrow Transplant. 2023 Nov 15. doi: 10.1038/s41409-023-02117.
    PubMed     Abstract available
    
    
    
22. HARBI S, Brac de la Perriere L, Bouchacourt B, Garciaz S, et al
    Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Bone Marrow Transplant. 2023 Nov 3. doi: 10.1038/s41409-023-02134.
    PubMed     Abstract available
    
    
    October 2023
23. YANG L, Lai X, Yang T, Lu Y, et al
    Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02137.
    PubMed     Abstract available
    
    
    
24. HUANG J, Feng B, Cheng Y, Xu L, et al
    Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed phenotype acute leukemia: a single center study.
    Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02141.
    PubMed    
    
    
    
25. CANCIO M, Troullioud Lucas AG, Bierings M, Klein E, et al
    Predictors of outcomes in hematopoietic cell transplantation for Fanconi anemia.
    Bone Marrow Transplant. 2023 Oct 17. doi: 10.1038/s41409-023-02121.
    PubMed     Abstract available
    
    
    September 2023
26. SATTY AM, Klein E, Mauguen A, Kunvarjee B, et al
    T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML.
    Bone Marrow Transplant. 2023 Sep 29. doi: 10.1038/s41409-023-02113.
    PubMed     Abstract available
    
    
    
27. CAO Y, Zhang C, Zhao X, Huang J, et al
    Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China.
    Bone Marrow Transplant. 2023 Sep 20. doi: 10.1038/s41409-023-02106.
    PubMed    
    
    
    
28. HARADA N, Okamura H, Makuuchi Y, Kuno M, et al
    Third HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide for relapsed acute leukemia.
    Bone Marrow Transplant. 2023 Sep 15. doi: 10.1038/s41409-023-02108.
    PubMed    
    
    
    
29. NAGLER A, Labopin M, Kroger N, Schroeder T, et al
    The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT.
    Bone Marrow Transplant. 2023 Sep 2. doi: 10.1038/s41409-023-02095.
    PubMed     Abstract available
    
    
    
30. JENG MY, Kong D, Rajalingam R, Lin RJ, et al
    Lack of disease control remains a major barrier to transplant for older patients with AML.
    Bone Marrow Transplant. 2023;58:1054-1056.
    PubMed    
    
    
    August 2023
31. REY G, Daguenet E, Bonjean P, Devillier R, et al
    Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC.
    Bone Marrow Transplant. 2023 Aug 31. doi: 10.1038/s41409-023-02082.
    PubMed     Abstract available
    
    
    
32. CHEN J, Labopin M, Pabst T, Zhang X, et al
    Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the globa
    Bone Marrow Transplant. 2023 Aug 28. doi: 10.1038/s41409-023-02070.
    PubMed     Abstract available
    
    
    
33. SANZ J, Labopin M, Pabst T, Versluis J, et al
    Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working P
    Bone Marrow Transplant. 2023 Aug 8. doi: 10.1038/s41409-023-02075.
    PubMed     Abstract available
    
    
    
34. KENT A, Schwartz M, McMahon C, Amaya M, et al
    Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse.
    Bone Marrow Transplant. 2023;58:849-854.
    PubMed     Abstract available
    
    
    
35. STYCZYNSKI J, Tridello G, Koster L, Knelange N, et al
    Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT.
    Bone Marrow Transplant. 2023;58:881-892.
    PubMed     Abstract available
    
    
    July 2023
36. RIEGER MJ, Stolz SM, Muller AM, Schwotzer R, et al
    Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm.
    Bone Marrow Transplant. 2023 Jul 21. doi: 10.1038/s41409-023-02042.
    PubMed     Abstract available
    
    
    
37. YANADA M, Shimomura Y, Mizuno S, Matsuda K, et al
    External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia.
    Bone Marrow Transplant. 2023 Jul 13. doi: 10.1038/s41409-023-02037.
    PubMed     Abstract available
    
    
    
38. GAVRIILAKI E, Sakellari I, Labopin M, Bornhauser M, et al
    Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Ac
    Bone Marrow Transplant. 2023 Jul 7. doi: 10.1038/s41409-023-02028.
    PubMed     Abstract available
    
    
    
39. SHEN Y, Zhang T, Zhang L, Zhen S, et al
    Allogeneic stem cell transplantation can prolong the survival of patients with NUP98-rearranged acute myeloid leukemia.
    Bone Marrow Transplant. 2023 Jul 7. doi: 10.1038/s41409-023-02030.
    PubMed    
    
    
    
40. NAGLER A, Labopin M, Mielke S, Passweg J, et al
    Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT.
    Bone Marrow Transplant. 2023;58:791-800.
    PubMed     Abstract available
    
    
    
41. FERNANDO F, Innes AJ, Claudiani S, Pryce A, et al
    The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.
    Bone Marrow Transplant. 2023;58:826-828.
    PubMed    
    
    
    
42. BARANWAL A, Chhetri R, Yeung D, Clark M, et al
    Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.
    Bone Marrow Transplant. 2023;58:769-776.
    PubMed     Abstract available
    
    
    June 2023
43. MAFFINI E, Ngoya M, Galimard JE, Harbi S, et al
    Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Bone Marrow Transplant. 2023 Jun 29. doi: 10.1038/s41409-023-02027.
    PubMed     Abstract available
    
    
    
44. CASSANELLO G, Serpenti F, Bagnoli F, Saporiti G, et al
    Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
    Bone Marrow Transplant. 2023 Jun 24. doi: 10.1038/s41409-023-02023.
    PubMed    
    
    
    
45. TOURNILHAC O, van Gelder M, Eikema DJ, Zinger N, et al
    The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2023;58:621-624.
    PubMed     Abstract available
    
    
    May 2023
46. NAGLER A, Labopin M, Swoboda R, Kulagin A, et al
    Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and
    Bone Marrow Transplant. 2023 May 30. doi: 10.1038/s41409-023-02012.
    PubMed     Abstract available
    
    
    
47. INOUE Y, Morishima S, Kato K, Ito A, et al
    Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2023 May 12. doi: 10.1038/s41409-023-02002.
    PubMed     Abstract available
    
    
    
48. BARON F, Ruggeri A, Peczynski C, Labopin M, et al
    Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2023 May 10. doi: 10.1038/s41409-023-02000.
    PubMed     Abstract available
    
    
    
49. FILIPPINI VELAZQUEZ G, Labopin M, Tischer J, Raiola AM, et al
    Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Bone Marrow Transplant. 2023 May 9. doi: 10.1038/s41409-023-01985.
    PubMed     Abstract available
    
    
    
50. HIRSCHBUHL K, Labopin M, Polge E, Blaise D, et al
    Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2023 May 5. doi: 10.1038/s41409-023-01966.
    PubMed     Abstract available
    
    
    April 2023
51. GAO Y, Wu H, Shi Z, Gao F, et al
    Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Apr 29. doi: 10.1038/s41409-023-01989.
    PubMed     Abstract available
    
    
    
52. NAKAYA Y, Nakamae H, Harada N, Okamura H, et al
    Effect of graft cell dose on second transplantation from a haploidentical donor with post-transplantation cyclophosphamide for relapsed/refractory acute leukemia.
    Bone Marrow Transplant. 2023 Apr 28. doi: 10.1038/s41409-023-01986.
    PubMed    
    
    
    
53. YUAN XL, Lai XY, Wu YB, Yang LX, et al
    A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation.
    Bone Marrow Transplant. 2023 Apr 18. doi: 10.1038/s41409-023-01979.
    PubMed     Abstract available
    
    
    
54. ABOU DALLE I, Labopin M, Kroger N, Schroeder T, et al
    Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2023 Apr 11. doi: 10.1038/s41409-023-01961.
    PubMed     Abstract available
    
    
    
55. KONG J, Zheng FM, Wang ZD, Zhang YY, et al
    Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2023 Apr 6. doi: 10.1038/s41409-023-01973.
    PubMed     Abstract available
    
    
    
56. JAMY O, Diebold K, Davis K, Bachiashvili K, et al
    Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia.
    Bone Marrow Transplant. 2023 Apr 3. doi: 10.1038/s41409-023-01977.
    PubMed    
    
    
    
57. PUCKRIN R, Owen C, Fontaine A, Peters A, et al
    Allogeneic hematopoietic cell transplantation for Richter transformation of chronic lymphocytic leukemia: an intention-to-transplant analysis.
    Bone Marrow Transplant. 2023 Apr 1. doi: 10.1038/s41409-023-01978.
    PubMed    
    
    
    March 2023
58. BUG G, Labopin M, Niittyvuopio R, Stelljes M, et al
    Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2023 Mar 31. doi: 10.1038/s41409-023-01965.
    PubMed     Abstract available
    
    
    
59. FUJI S, Inoue Y, Makiyama J, Nakano N, et al
    The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2023 Mar 25. doi: 10.1038/s41409-023-01969.
    PubMed    
    
    
    
60. FAN J, Lu R, Zhu J, Guo X, et al
    Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2023 Mar 24. doi: 10.1038/s41409-023-01948.
    PubMed     Abstract available
    
    
    
61. EL CHEIKH J, Bidaoui G, Atoui A, Terro K, et al
    Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study.
    Bone Marrow Transplant. 2023 Mar 13. doi: 10.1038/s41409-023-01947.
    PubMed     Abstract available
    
    
    
62. PFEIFFER T, Li Y, Ashcraft E, Karol SE, et al
    Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.
    Bone Marrow Transplant. 2023;58:328-331.
    PubMed    
    
    
    
63. MARIOTTI J, Magri F, Giordano L, De Philippis C, et al
    EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide.
    Bone Marrow Transplant. 2023;58:247-256.
    PubMed     Abstract available
    
    
    February 2023
64. NAGLER A, Labopin M, Swoboda R, Kulagin A, et al
    Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Par
    Bone Marrow Transplant. 2023 Feb 23. doi: 10.1038/s41409-023-01940.
    PubMed     Abstract available
    
    
    
65. VINCI L, Flotho C, Noellke P, Lebrecht D, et al
    Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft.
    Bone Marrow Transplant. 2023 Feb 23. doi: 10.1038/s41409-023-01942.
    PubMed    
    
    
    
66. MASSEI MS, Capolsini I, Mastrodicasa E, Perruccio K, et al
    HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia.
    Bone Marrow Transplant. 2023 Feb 11:1-8. doi: 10.1038/s41409-023-01911.
    PubMed     Abstract available
    
    
    
67. MICHEL C, Robin M, Morisset S, Blaise D, et al
    Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS.
    Bone Marrow Transplant. 2023 Feb 11. doi: 10.1038/s41409-023-01931.
    PubMed     Abstract available
    
    
    
68. GIEBEL S, Labopin M, Socie G, Aljurf M, et al
    Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EB
    Bone Marrow Transplant. 2023 Feb 1. doi: 10.1038/s41409-023-01917.
    PubMed     Abstract available
    
    
    
69. WANG M, Wang B, Xu LP, Wang Y, et al
    The lower relapse rate and better survival advantages of haploidentical allograft compared with HLA-matched sibling donor allografts for intermediate- and adverse-risk AML patients with pretransplantation minimal residual disease.
    Bone Marrow Transplant. 2023;58:215-218.
    PubMed    
    
    
    January 2023
70. SUN YQ, Zhang XH, Jiang Q, Jiang H, et al
    Comparison of haploidentical hematopoietic stem cell transplantation with chemotherapy in older adults with acute myeloid leukemia.
    Bone Marrow Transplant. 2023 Jan 25. doi: 10.1038/s41409-023-01925.
    PubMed     Abstract available
    
    
    
71. TOKUNAGA M, Nakano N, Fuji S, Wake A, et al
    Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study.
    Bone Marrow Transplant. 2023 Jan 21. doi: 10.1038/s41409-023-01919.
    PubMed    
    
    
    
72. GIEBEL S, Labopin M, Houhou M, Caillot D, et al
    Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2023 Jan 7. doi: 10.1038/s41409-022-01904.
    PubMed     Abstract available
    
    
    December 2022
73. WALTER RB, Sandmaier BM, Othus M, Orvain C, et al
    Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.
    Bone Marrow Transplant. 2022 Dec 28. doi: 10.1038/s41409-022-01909.
    PubMed     Abstract available
    
    
    
74. RAMANATHAN M, Kim S, He N, Chen M, et al
    The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study.
    Bone Marrow Transplant. 2022 Dec 21. doi: 10.1038/s41409-022-01896.
    PubMed     Abstract available
    
    
    
75. MURPHY LA, Miller K, Winters AC, Franklin ARK, et al
    Time to transplantation and pediatric acute myeloid leukemia outcomes.
    Bone Marrow Transplant. 2022 Dec 10. doi: 10.1038/s41409-022-01893.
    PubMed    
    
    
    
76. SWOBODA R, Labopin M, Giebel S, Schroeder T, et al
    Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working
    Bone Marrow Transplant. 2022 Dec 2. doi: 10.1038/s41409-022-01882.
    PubMed     Abstract available
    
    
    
77. MAURER SM, Linder KA, Kauffman CA, McDonald PJ, et al
    Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies.
    Bone Marrow Transplant. 2022;57:1820-1826.
    PubMed     Abstract available
    
    
    November 2022
78. LUO C, Wu G, Huang X, Ding Y, et al
    Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.
    Bone Marrow Transplant. 2022 Nov 10. pii: 10.1038/s41409-022-01865.
    PubMed     Abstract available
    
    
    
79. FINKE J, Schmoor C, Stelljes M, Burchert A, et al
    Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
    Bone Marrow Transplant. 2022;57:1664-1670.
    PubMed     Abstract available
    
    
    October 2022
80. BARON F, Labopin M, Tischer J, Ciceri F, et al
    Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia.
    Bone Marrow Transplant. 2022 Oct 24. pii: 10.1038/s41409-022-01856.
    PubMed    
    
    
    
81. NAGLER A, Ngoya M, Galimard JE, Labopin M, et al
    Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT.
    Bone Marrow Transplant. 2022 Oct 24. pii: 10.1038/s41409-022-01853.
    PubMed    
    
    
    
82. YAO Z, Gu B, Zhang Y, Qi J, et al
    CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2022 Oct 17. pii: 10.1038/s41409-022-01845.
    PubMed    
    
    
    
83. BANET A, Bazarbachi A, Labopin M, Stocker N, et al
    Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2022 Oct 12. pii: 10.1038/s41409-022-01841.
    PubMed     Abstract available
    
    
    
84. NAGLER A, Peczynski C, Dholaria B, Labopin M, et al
    Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
    Bone Marrow Transplant. 2022 Oct 7. pii: 10.1038/s41409-022-01834.
    PubMed    
    
    
    
85. KONUMA T, Harada K, Kondo T, Masuko M, et al
    Salvage single-unit unrelated cord blood transplantation for graft failure following initial allogeneic transplantation in adult acute myeloid leukemia: trends in outcomes over the past 20 years.
    Bone Marrow Transplant. 2022 Oct 4. pii: 10.1038/s41409-022-01840.
    PubMed    
    
    
    
86. BACKHAUS D, Brauer D, Pointner R, Bischof L, et al
    A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.
    Bone Marrow Transplant. 2022 Oct 4. pii: 10.1038/s41409-022-01833.
    PubMed     Abstract available
    
    
    September 2022
87. YI ES, Kim SK, Ju HY, Lee JW, et al
    Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group.
    Bone Marrow Transplant. 2022 Sep 27. pii: 10.1038/s41409-022-01826.
    PubMed     Abstract available
    
    
    
88. SONG GY, Kim T, Ahn SY, Jung SH, et al
    Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia.
    Bone Marrow Transplant. 2022 Sep 23. pii: 10.1038/s41409-022-01817.
    PubMed     Abstract available
    
    
    
89. GAVRIILAKI E, Labopin M, Sakellari I, Salmenniemi U, et al
    Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leuk
    Bone Marrow Transplant. 2022 Sep 22. pii: 10.1038/s41409-022-01830.
    PubMed     Abstract available
    
    
    
90. NAGLER A, Ngoya M, Jacques-Emmanuel G, Labopin M, et al
    Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT.
    Bone Marrow Transplant. 2022 Sep 16. pii: 10.1038/s41409-022-01825.
    PubMed     Abstract available
    
    
    
91. PIZZOLA CJ, Cioccio J, Rakszawski KL, Nickolich M, et al
    Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities.
    Bone Marrow Transplant. 2022 Sep 12. pii: 10.1038/s41409-022-01821.
    PubMed    
    
    
    
92. ATSUTA Y, Sugita J, Nakamae H, Maruyama Y, et al
    Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation.
    Bone Marrow Transplant. 2022 Sep 12. pii: 10.1038/s41409-022-01822.
    PubMed     Abstract available
    
    
    
93. VAUGHN JL, Brown S, Papadopoulos EB, Jakubowski AA, et al
    CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era.
    Bone Marrow Transplant. 2022 Sep 8. pii: 10.1038/s41409-022-01783.
    PubMed    
    
    
    
94. SPYRIDONIDIS A, Labopin M, Brissot E, Moiseev I, et al
    Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2022 Sep 7. pii: 10.1038/s41409-022-01816.
    PubMed     Abstract available
    
    
    
95. TANG B, Cai Z, Wang Z, Lin D, et al
    Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2022 Sep 2. pii: 10.1038/s41409-022-01797.
    PubMed     Abstract available
    
    
    August 2022
96. QI HZ, Xu J, Yang QQ, Lin R, et al
    Effect of pediatric- versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission.
    Bone Marrow Transplant. 2022 Aug 30. pii: 10.1038/s41409-022-01796.
    PubMed     Abstract available
    
    
    
97. RODRIGUEZ-ARBOLI E, Orvain C, Othus M, Walter RB, et al
    Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2022 Aug 27. pii: 10.1038/s41409-022-01794.
    PubMed    
    
    
    
98. BARANWAL A, Nanaa A, Viswanatha D, He R, et al
    Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia.
    Bone Marrow Transplant. 2022 Aug 20. pii: 10.1038/s41409-022-01776.
    PubMed    
    
    
    
99. SUGITA J, Atsuta Y, Nakamae H, Maruyama Y, et al
    Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation.
    Bone Marrow Transplant. 2022 Aug 20. pii: 10.1038/s41409-022-01770.
    PubMed     Abstract available
    
    
    
100. BARON F, Labopin M, Tischer J, Ciceri F, et al
     Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia.
     Bone Marrow Transplant. 2022 Aug 17. pii: 10.1038/s41409-022-01781.
     PubMed     Abstract available
     
     
     July 2022
101. EL CHAER F, Ballen KK
     Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?
     Bone Marrow Transplant. 2022 Jul 28. pii: 10.1038/s41409-022-01765.
     PubMed    
     
     
     
102. HONG S, Rybicki L, Gurnari C, Pagliuca S, et al
     Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes.
     Bone Marrow Transplant. 2022 Jul 27. pii: 10.1038/s41409-022-01762.
     PubMed    
     
     
     
103. MAFFINI E, Labopin M, Beelen DW, Kroeger N, et al
     Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transpl
     Bone Marrow Transplant. 2022 Jul 14. pii: 10.1038/s41409-022-01748.
     PubMed     Abstract available
     
     
     
104. JAMY O, Arora S, Meredith R, Salzman D, et al
     Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.
     Bone Marrow Transplant. 2022 Jul 9. pii: 10.1038/s41409-022-01757.
     PubMed    
     
     
     
105. DING L, Han DM, Yan HM, Zhou JX, et al
     Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients.
     Bone Marrow Transplant. 2022;57:1086-1094.
     PubMed     Abstract available
     
     
     
106. NABERGOJ M, Mauff K, Beelen D, Ganser A, et al
     Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT.
     Bone Marrow Transplant. 2022;57:1072-1078.
     PubMed     Abstract available
     
     
     June 2022
107. NAGLER A, Labopin M, Cornelissen JJ, Forcade E, et al
     Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Socie
     Bone Marrow Transplant. 2022 Jun 30. pii: 10.1038/s41409-022-01742.
     PubMed     Abstract available
     
     
     
108. DEVILLIER R, Galimard JE, Labopin M, Blaise D, et al
     Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.
     Bone Marrow Transplant. 2022 Jun 25. pii: 10.1038/s41409-022-01674.
     PubMed     Abstract available
     
     
     
109. LAZZARI L, Balaguer-Rosello A, Montoro J, Greco R, et al
     Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
     Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01725.
     PubMed     Abstract available
     
     
     
110. OHMOTO A, Fuji S, Shultes KC, Savani BN, et al
     Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
     Bone Marrow Transplant. 2022;57:874-880.
     PubMed     Abstract available
     
     
     
111. KEVLICIUS L, Cepulyte R, Vasilevska D, Griskevicius L, et al
     Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies.
     Bone Marrow Transplant. 2022;57:1034-1037.
     PubMed    
     
     
     
112. MAAKARON JE, Zhang MJ, Chen K, Abhyankar S, et al
     Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.
     Bone Marrow Transplant. 2022;57:911-917.
     PubMed     Abstract available
     
     
     
113. ONIDA F, Sbianchi G, Radujkovic A, Sockel K, et al
     Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.
     Bone Marrow Transplant. 2022;57:896-902.
     PubMed     Abstract available
     
     
     May 2022
114. GUIJARRO F, Bataller A, Diaz-Beya M, Garrido A, et al
     Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan.
     Bone Marrow Transplant. 2022 May 28. pii: 10.1038/s41409-022-01703.
     PubMed     Abstract available
     
     
     
115. ANDERSSON BS, Thall PF, Ma J, Valdez BC, et al
     A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan +/- clofarabine in allogeneic stem cell transplantation.
     Bone Marrow Transplant. 2022 May 24. pii: 10.1038/s41409-022-01705.
     PubMed     Abstract available
     
     
     
116. DUQUE-AFONSO J, Finke J, Labopin M, Craddock C, et al
     Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
     Bone Marrow Transplant. 2022 May 14. pii: 10.1038/s41409-022-01646.
     PubMed     Abstract available
     
     
     
117. DANYLESKO I, Peczynski C, Labopin M, Polge E, et al
     Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT.
     Bone Marrow Transplant. 2022 May 13. pii: 10.1038/s41409-022-01695.
     PubMed     Abstract available
     
     
     
118. YOKOYAMA H, Kanaya M, Iemura T, Hirayama M, et al
     Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch.
     Bone Marrow Transplant. 2022 May 10. pii: 10.1038/s41409-022-01700.
     PubMed     Abstract available
     
     
     April 2022
119. NAGLER A, Peczynski C, Dholaria B, Labopin M, et al
     Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
     Bone Marrow Transplant. 2022 Apr 30. pii: 10.1038/s41409-022-01693.
     PubMed     Abstract available
     
     
     
120. DELIA M, Carluccio P, Gagliardi VP, Mestice A, et al
     Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation.
     Bone Marrow Transplant. 2022 Apr 19. pii: 10.1038/s41409-022-01676.
     PubMed    
     
     
     
121. BONIFAZI F, Pavoni C, Peccatori J, Giglio F, et al
     Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
     Bone Marrow Transplant. 2022 Apr 12. pii: 10.1038/s41409-022-01626.
     PubMed     Abstract available
     
     
     
122. RODRIGUEZ-ARBOLI E, Labopin M, Eder M, Brecht A, et al
     Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
     Bone Marrow Transplant. 2022 Apr 7. pii: 10.1038/s41409-022-01611.
     PubMed     Abstract available
     
     
     
123. HAROON A, Alfraih F, Hanbali A, Kotb A, et al
     Allogeneic transplant compared to pediatric-inspired therapy for Philadelphia chromosome-negative adolescent and adult ALL in first complete remission.
     Bone Marrow Transplant. 2022;57:593-597.
     PubMed     Abstract available
     
     
     
124. GALLI E, Metafuni E, Giammarco S, Limongiello MA, et al
     Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants.
     Bone Marrow Transplant. 2022;57:532-537.
     PubMed     Abstract available
     
     
     March 2022
125. WANG L, Gao W, Wang L, Wan M, et al
     Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial.
     Bone Marrow Transplant. 2022 Mar 29. pii: 10.1038/s41409-022-01639.
     PubMed    
     
     
     
126. JIANG JL, Chen M, Wang LN, Wan M, et al
     Double alkylators based conditioning reduced the relapse rate after allogeneic peripheral blood stem cell transplantation in adult patients with myeloid malignancies: a single arm phase II study.
     Bone Marrow Transplant. 2022 Mar 24. pii: 10.1038/s41409-022-01643.
     PubMed    
     
     
     
127. OKADA Y, Nakasone H, Nakamura Y, Kawamura M, et al
     Prognostic impact of chromosomal changes at relapse after allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
     Bone Marrow Transplant. 2022 Mar 21. pii: 10.1038/s41409-022-01635.
     PubMed     Abstract available
     
     
     
128. JIMENEZ JIMENEZ AM, De Lima M, Komanduri KV, Wang TP, et al
     Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
     Bone Marrow Transplant. 2022 Mar 16. pii: 10.1038/s41409-022-01625.
     PubMed    
     
     
     
129. HERNANDEZ-BOLUDA JC, Pereira A, Zinger N, Gras L, et al
     Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.
     Bone Marrow Transplant. 2022;57:416-422.
     PubMed     Abstract available
     
     
     
130. HAN S, Zhou L, Chen Y, Zhou X, et al
     The role of allogeneic haematopoietic cell transplantation as consolidation after anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia: a prospective cohort study.
     Bone Marrow Transplant. 2022;57:513-516.
     PubMed    
     
     
     
131. FUJI S, Hirakawa T, Takano K, Doki N, et al
     Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group.
     Bone Marrow Transplant. 2022;57:479-486.
     PubMed     Abstract available
     
     
     February 2022
132. ZHANG Z, Hasegawa Y, Hashimoto D, Senjo H, et al
     Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2022 Feb 28. pii: 10.1038/s41409-022-01619.
     PubMed     Abstract available
     
     
     
133. LINDAHL H, Vonlanthen S, Valentini D, Bjorklund AT, et al
     Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
     Bone Marrow Transplant. 2022 Feb 24. pii: 10.1038/s41409-022-01615.
     PubMed     Abstract available
     
     
     
134. CANDONI A, Lazzarotto D, Rambaldi A, Dubbini MV, et al
     Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study.
     Bone Marrow Transplant. 2022 Feb 24. pii: 10.1038/s41409-022-01618.
     PubMed    
     
     
     
135. PIEMONTESE S, Lazzari L, Ruggeri A, Marcatti M, et al
     Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience.
     Bone Marrow Transplant. 2022 Feb 5. pii: 10.1038/s41409-022-01600.
     PubMed    
     
     
     
136. NAGLER A, Labopin M, Huang XJ, Blaise D, et al
     Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.
     Bone Marrow Transplant. 2022 Feb 1. pii: 10.1038/s41409-021-01537.
     PubMed     Abstract available
     
     
     
137. YEH AC, O'Donnell PV, Schoch G, Martin PJ, et al
     Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
     Bone Marrow Transplant. 2022;57:198-206.
     PubMed     Abstract available
     
     
     
138. POLLYEA DA, Winters A, McMahon C, Schwartz M, et al
     Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
     Bone Marrow Transplant. 2022;57:160-166.
     PubMed     Abstract available
     
     
     January 2022
139. BATTIPAGLIA G, Galimard JE, Labopin M, Raiola AM, et al
     Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.
     Bone Marrow Transplant. 2022 Jan 25. pii: 10.1038/s41409-022-01577.
     PubMed     Abstract available
     
     
     
140. NI F, Yin ETS, Zhou L, Zhao H, et al
     Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
     Bone Marrow Transplant. 2022 Jan 24. pii: 10.1038/s41409-021-01554.
     PubMed    
     
     
     
141. UTSUNOMIYA A, Tokunaga M, Nakano N, Fujiwara H, et al
     Long-term follow-up of patients with ATL after autologous stem cell transplantation.
     Bone Marrow Transplant. 2022 Jan 23. pii: 10.1038/s41409-021-01412.
     PubMed    
     
     
     
142. SWOBODA R, Labopin M, Giebel S, Angelucci E, et al
     Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukem
     Bone Marrow Transplant. 2022 Jan 15. pii: 10.1038/s41409-021-01550.
     PubMed     Abstract available
     
     
     
143. SHIMONI A
     Relapse of acute leukemia after a second allogeneic stem- cell transplantation; Is there any hope for cure?
     Bone Marrow Transplant. 2022 Jan 14. pii: 10.1038/s41409-021-01508.
     PubMed    
     
     
     
144. SHIMONI A, Labopin M, Angelucci E, Blaise D, et al
     The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML.
     Bone Marrow Transplant. 2022 Jan 13. pii: 10.1038/s41409-021-01493.
     PubMed     Abstract available
     
     
     
145. EL HUSSEIN S, DiNardo CD, Takahashi K, Khoury JD, et al
     Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
     Bone Marrow Transplant. 2022 Jan 7. pii: 10.1038/s41409-021-01538.
     PubMed     Abstract available
     
     
     
146. ANDOLINA JR, Wang YC, Ji L, Freyer DR, et al
     Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience.
     Bone Marrow Transplant. 2022 Jan 6. pii: 10.1038/s41409-021-01558.
     PubMed     Abstract available
     
     
     
147. KANDA J, Hayashi H, Ruggeri A, Kimura F, et al
     The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.
     Bone Marrow Transplant. 2022;57:57-64.
     PubMed     Abstract available
     
     
     
148. CAI J, Kim S
     Case-cohort design in hematopoietic cell transplant studies.
     Bone Marrow Transplant. 2022;57:1-5.
     PubMed     Abstract available
     
     
     December 2021
149. BETHGE WA, Eyrich M, Mielke S, Meisel R, et al
     Results of a multicenter phase I/II trial of TCRalphabeta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients.
     Bone Marrow Transplant. 2021 Dec 24. pii: 10.1038/s41409-021-01551.
     PubMed     Abstract available
     
     
     
150. LIANG EC, Chen C, Lu R, Mannis GN, et al
     Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.
     Bone Marrow Transplant. 2021;56:3091-3093.
     PubMed     Abstract available
     
     
     
151. KUROSAWA S, Shimomura Y, Itonaga H, Najima Y, et al
     Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
     Bone Marrow Transplant. 2021;56:3008-3015.
     PubMed     Abstract available
     
     
     
152. SHARMA A, Huang S, Li Y, Brooke RJ, et al
     Outcomes of pediatric patients with therapy-related myeloid neoplasms.
     Bone Marrow Transplant. 2021;56:2997-3007.
     PubMed     Abstract available
     
     
     November 2021
153. SHUMILOV E, Shakhanova I, Flach J, Schmidt N, et al
     Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation.
     Bone Marrow Transplant. 2021 Nov 13. pii: 10.1038/s41409-021-01521.
     PubMed     Abstract available
     
     
     
154. SCHETELIG J, Hoek J, Stilgenbauer S, Middeke JM, et al
     Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study.
     Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01524.
     PubMed    
     
     
     
155. SCHETELIG J, Chevallier P, van Gelder M, Hoek J, et al
     Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
     Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01516.
     PubMed    
     
     
     
156. SCHMID C, Labopin M, Schaap N, Veelken H, et al
     Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.
     Bone Marrow Transplant. 2021 Nov 8. pii: 10.1038/s41409-021-01515.
     PubMed     Abstract available
     
     
     
157. MOHTY R, Gauthier J
     Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors.
     Bone Marrow Transplant. 2021;56:2630-2636.
     PubMed     Abstract available
     
     
     
158. BARON F, Ngoya M, Labopin M, Cornelissen JJ, et al
     Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT.
     Bone Marrow Transplant. 2021;56:2742-2748.
     PubMed     Abstract available
     
     
     
159. KRIEGER E, Qayyum R, Keating A, Toor A, et al
     Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML.
     Bone Marrow Transplant. 2021;56:2714-2722.
     PubMed     Abstract available
     
     
     October 2021
160. TIEN FM, Tsai CH, Huang SC, Liu JH, et al
     Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission.
     Bone Marrow Transplant. 2021 Oct 20. pii: 10.1038/s41409-021-01454.
     PubMed     Abstract available
     
     
     
161. BAZARBACHI A
     Exciting times ahead for older patients with acute myeloid leukemia: azacitidine and venetoclax followed by allogeneic hematopoietic cell transplantation.
     Bone Marrow Transplant. 2021 Oct 13. pii: 10.1038/s41409-021-01474.
     PubMed    
     
     
     
162. YANADA M, Ota S, Mukae J, Nara M, et al
     Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis.
     Bone Marrow Transplant. 2021 Oct 13. pii: 10.1038/s41409-021-01501.
     PubMed     Abstract available
     
     
     
163. KOBAYASHI S, Kanda Y, Konuma T, Inamoto Y, et al
     Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
     Bone Marrow Transplant. 2021 Oct 8. pii: 10.1038/s41409-021-01485.
     PubMed     Abstract available
     
     
     
164. POIRE X, Graux C, Ory A, Herman J, et al
     Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective s
     Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01464.
     PubMed    
     
     
     
165. MASOURIDI-LEVRAT S, Olavarria E, Iacobelli S, Aljurf M, et al
     Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Workin
     Bone Marrow Transplant. 2021 Oct 1. pii: 10.1038/s41409-021-01472.
     PubMed     Abstract available
     
     
     September 2021
166. JIMENEZ JIMENEZ AM, De Lima M, Komanduri KV, Wang TP, et al
     An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
     Bone Marrow Transplant. 2021 Sep 28. pii: 10.1038/s41409-021-01450.
     PubMed     Abstract available
     
     
     
167. HU K, Wang Y, Teng X, Hu Y, et al
     Cell subsets and cytokine dynamics in cerebrospinal fluid after CAR-T cell therapy for B-cell acute lymphoblastic leukemia with central nervous system involvement.
     Bone Marrow Transplant. 2021 Sep 27. pii: 10.1038/s41409-021-01471.
     PubMed    
     
     
     
168. YOKOYAMA H, Hirayama M, Takahashi Y, Uchida N, et al
     Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation.
     Bone Marrow Transplant. 2021 Sep 24. pii: 10.1038/s41409-021-01469.
     PubMed     Abstract available
     
     
     
169. ROCHA V, Arcuri LJ, Seber A, Colturato V, et al
     Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia.
     Bone Marrow Transplant. 2021 Sep 21. pii: 10.1038/s41409-021-01453.
     PubMed     Abstract available
     
     
     
170. PINCEZ T, Santiago R, Bittencourt H, Louis I, et al
     Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children.
     Bone Marrow Transplant. 2021 Sep 2. pii: 10.1038/s41409-021-01408.
     PubMed     Abstract available
     
     
     
171. PHAM B, Hoeg R, Krishnan R, Richman C, et al
     Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome.
     Bone Marrow Transplant. 2021 Sep 1. pii: 10.1038/s41409-021-01444.
     PubMed     Abstract available
     
     
     
172. GALE RP, Schiffer CA, Lazarus HM
     Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?
     Bone Marrow Transplant. 2021;56:2046-2049.
     PubMed    
     
     
     August 2021
173. INOUE Y, Nakano N, Fuji S, Eto T, et al
     Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.
     Bone Marrow Transplant. 2021 Aug 31. pii: 10.1038/s41409-021-01445.
     PubMed     Abstract available
     
     
     
174. XU LP, Lu PH, Wu DP, Sun ZM, et al
     Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group.
     Bone Marrow Transplant. 2021 Aug 25. pii: 10.1038/s41409-021-01431.
     PubMed     Abstract available
     
     
     
175. TAMAI H, Tajika K, Nakayama K, Arai A, et al
     Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide.
     Bone Marrow Transplant. 2021 Aug 12. pii: 10.1038/s41409-021-01432.
     PubMed    
     
     
     
176. ABOU DALLE I, Bazarbachi A
     Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation.
     Bone Marrow Transplant. 2021 Aug 10. pii: 10.1038/s41409-021-01434.
     PubMed    
     
     
     
177. CRUIJSEN M, Hilberink JR, van der Velden WJFM, Jansen JH, et al
     Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.
     Bone Marrow Transplant. 2021;56:1964-1970.
     PubMed     Abstract available
     
     
     
178. RUGGERI L, Vago L, Eikema DJ, de Wreede LC, et al
     Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT.
     Bone Marrow Transplant. 2021;56:1900-1907.
     PubMed     Abstract available
     
     
     July 2021
179. AKAHOSHI Y, Arai Y, Nishiwaki S, Tachibana T, et al
     Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report
     Bone Marrow Transplant. 2021 Jul 30. pii: 10.1038/s41409-021-01422.
     PubMed     Abstract available
     
     
     
180. NIEDERWIESER C, Morozova E, Zubarovskaya L, Zabelina T, et al
     Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML.
     Bone Marrow Transplant. 2021 Jul 30. pii: 10.1038/s41409-021-01410.
     PubMed     Abstract available
     
     
     
181. ZUCENKA A, Vaitekenaite V, Maneikis K, Davainis L, et al
     Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
     Bone Marrow Transplant. 2021 Jul 17. pii: 10.1038/s41409-021-01416.
     PubMed     Abstract available
     
     
     
182. KONUMA T, Kondo T, Masuko M, Shimizu H, et al
     Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
     Bone Marrow Transplant. 2021 Jul 16. pii: 10.1038/s41409-021-01409.
     PubMed     Abstract available
     
     
     
183. JENTZSCH M, Grimm J, Bill M, Kupper J, et al
     Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
     Bone Marrow Transplant. 2021 Jul 15. pii: 10.1038/s41409-021-01407.
     PubMed    
     
     
     
184. GREIL C, Engelhardt M, Ihorst G, Duque-Afonso J, et al
     Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.
     Bone Marrow Transplant. 2021 Jul 8. pii: 10.1038/s41409-021-01366.
     PubMed    
     
     
     June 2021
185. GEVA M, Pryce A, Shouval R, Fein JA, et al
     High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
     Bone Marrow Transplant. 2021 Jun 29. pii: 10.1038/s41409-021-01377.
     PubMed     Abstract available
     
     
     
186. CHO BS, Min GJ, Park SS, Park S, et al
     Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.
     Bone Marrow Transplant. 2021 Jun 28. pii: 10.1038/s41409-021-01384.
     PubMed     Abstract available
     
     
     
187. SHIMOMURA Y, Hara M, Hirabayashi S, Kondo T, et al
     Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
     Bone Marrow Transplant. 2021 Jun 21. pii: 10.1038/s41409-021-01380.
     PubMed    
     
     
     
188. BRUZZESE A, Assanto GM, Diverio D, Quattrocchi L, et al
     Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience.
     Bone Marrow Transplant. 2021;56:1455-1457.
     PubMed    
     
     
     May 2021
189. WAIDHAUSER J, Labopin M, Esteve J, Kroger N, et al
     Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT.
     Bone Marrow Transplant. 2021 May 31. pii: 10.1038/s41409-021-01322.
     PubMed     Abstract available
     
     
     
190. MIKULSKA M, Tridello G, Hoek J, Gil L, et al
     Legionellosis after hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2021 May 22. pii: 10.1038/s41409-021-01333.
     PubMed     Abstract available
     
     
     
191. PERCIVAL ME, Wang HL, Zhang MJ, Saber W, et al
     Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
     Bone Marrow Transplant. 2021 May 20. pii: 10.1038/s41409-021-01353.
     PubMed    
     
     
     
192. BEAUVERD Y, Morin S, Stephan C, De Ramon Ortiz C, et al
     The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft.
     Bone Marrow Transplant. 2021 May 18. pii: 10.1038/s41409-021-01334.
     PubMed    
     
     
     
193. KANAAN SB, Delaney C, Milano F, Scaradavou A, et al
     Cord blood maternal microchimerism following unrelated cord blood transplantation.
     Bone Marrow Transplant. 2021;56:1090-1098.
     PubMed     Abstract available
     
     
     
194. QIAN CS, Ma X, Wang J, Wang TJ, et al
     PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.
     Bone Marrow Transplant. 2021;56:1003-1005.
     PubMed    
     
     
     April 2021
195. KHARFAN-DABAJA MA, Labopin M, Bazarbachi A, Ciceri F, et al
     Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT.
     Bone Marrow Transplant. 2021 Apr 30. pii: 10.1038/s41409-021-01317.
     PubMed     Abstract available
     
     
     
196. TOYODA K, Yasunaga JI, Choi I, Suehiro Y, et al
     The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation.
     Bone Marrow Transplant. 2021 Apr 29. pii: 10.1038/s41409-021-01311.
     PubMed    
     
     
     
197. RAGON BK
     FLT3-ITDos and FLT3-ITDon'ts: navigating maintenance therapy in FLT3-ITD-positive acute myeloid leukemia following stem cell transplantation.
     Bone Marrow Transplant. 2021 Apr 28. pii: 10.1038/s41409-021-01269.
     PubMed    
     
     
     
198. RUSSO D, Polverelli N, Malagola M, Farina M, et al
     Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey).
     Bone Marrow Transplant. 2021 Apr 19. pii: 10.1038/s41409-021-01287.
     PubMed     Abstract available
     
     
     
199. PERCIVAL ME, Wang HL, Zhang MJ, Saber W, et al
     Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
     Bone Marrow Transplant. 2021 Apr 16. pii: 10.1038/s41409-021-01261.
     PubMed     Abstract available
     
     
     
200. BADAR T, Szabo A, Litzow M, Burkart M, et al
     Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.
     Bone Marrow Transplant. 2021 Apr 6. pii: 10.1038/s41409-021-01279.
     PubMed     Abstract available
     
     
     
201. CHO H, Kim Y, Yoon JH, Lee J, et al
     Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia.
     Bone Marrow Transplant. 2021 Apr 6. pii: 10.1038/s41409-021-01253.
     PubMed     Abstract available
     
     
     February 2021
202. TANG X, Valdez BC, Ma Y, Zhang Q, et al
     Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2021 Feb 26. pii: 10.1038/s41409-021-01238.
     PubMed     Abstract available
     
     
     
203. RAUTENBERG C, Bergmann A, Pechtel S, Fischermanns C, et al
     Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation.
     Bone Marrow Transplant. 2021;56:442-450.
     PubMed     Abstract available
     
     
     
204. DEYA-MARTINEZ A, Alonso-Saladrigues A, Garcia AP, Faura A, et al
     Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia.
     Bone Marrow Transplant. 2021;56:376-386.
     PubMed     Abstract available
     
     
     November 2020
205. HUA J, Zhang J, Zhang X, Wu X, et al
     Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2020 Nov 24. pii: 10.1038/s41409-020-01140.
     PubMed     Abstract available
     
     
     
206. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
     ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.
     Bone Marrow Transplant. 2020 Nov 19. pii: 10.1038/s41409-020-01129.
     PubMed     Abstract available
     
     
     October 2020
207. LOKE J, Labopin M, Craddock C, Niederwieser D, et al
     Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.
     Bone Marrow Transplant. 2020 Oct 2. pii: 10.1038/s41409-020-01072.
     PubMed     Abstract available
     
     
     September 2020
208. ZAMPERLINI-NETTO G, Fernandes JF, Garcia JL, Ribeiro AAF, et al
     COVID-19 after hematopoietic stem cell transplantation: report of two children.
     Bone Marrow Transplant. 2020 Sep 16. pii: 10.1038/s41409-020-01041.
     PubMed    
     
     
     
209. JIANG S, Fan Y, Fang Y, Hou C, et al
     The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.
     Bone Marrow Transplant. 2020 Sep 5. pii: 10.1038/s41409-020-01048.
     PubMed     Abstract available
     
     
     August 2020
210. LU X, Tang LV, Wang HF, You Y, et al
     The great challenge of managing recipients of hematopoietic stem cell transplantation combined with COVID-19.
     Bone Marrow Transplant. 2020 Aug 25. pii: 10.1038/s41409-020-01035.
     PubMed    
     
     
     
211. MCCAUGHAN G, Ma D, Moore J
     Two cases of successful autologous stem cell transplantation in patients with multiple myeloma and concurrent chronic myeloid leukaemia.
     Bone Marrow Transplant. 2020 Aug 8. pii: 10.1038/s41409-020-01025.
     PubMed    
     
     
     May 2020
212. REES MJ, Spencer A, Browett P, Alvaro F, et al
     High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission.
     Bone Marrow Transplant. 2020 May 6. pii: 10.1038/s41409-020-0924.
     PubMed    
     
     
     March 2020
213. KANDA J, Umeda K, Kato K, Murata M, et al
     Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation.
     Bone Marrow Transplant. 2020 Mar 11. pii: 10.1038/s41409-020-0853.
     PubMed     Abstract available
     
     
     January 2020
214. WETHMAR K, Matern S, Esseling E, Angenendt L, et al
     Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.
     Bone Marrow Transplant. 2020 Jan 30. pii: 10.1038/s41409-020-0801.
     PubMed     Abstract available
     
     
     September 2019
215. AMBERGE S, Kramer M, Schrottner P, Heidrich K, et al
     Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome.
     Bone Marrow Transplant. 2019 Sep 18. pii: 10.1038/s41409-019-0678.
     PubMed     Abstract available
     
     
     August 2019
216. STYCZYNSKI J, Tridello G, Koster L, Iacobelli S, et al
     Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.
     Bone Marrow Transplant. 2019 Aug 27. pii: 10.1038/s41409-019-0624.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.